GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) has awarded approximately $450,000 to U.S. community-based organizations and institutions as part of the company’s 2021 Access to Excellent C...
GlobeNewswire · 2d ago
BRIEF-Global Blood Therapeutics Inc's Voxelotor To Receive Promising Innovative Medicine Designation In UK · 3d ago
GBT's Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK
Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT), a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, announced today that
Benzinga · 3d ago
Global Blood Therapeutics' Voxelotor Receives Promising Innovative Medicine Designation in UK; Shares Up Pre-Bell
MT Newswires · 3d ago
BRIEF-Global Blood Therapeutics Says In HOPE-KIDS 1 Study, Oxbryta Was Well Tolerated And No New Adverse Safety Signals Were Detected · 6d ago
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation Two Real-world Data Studies Demonstrated Sustained Improvements in Hemoglobin with Oxbryta Consistent with Results from the Phase 3 HOPE Study SOUTH SAN FRANCISCO, Calif., June 11, 2021...
GlobeNewswire · 6d ago
Global Sickle Cell Anemia Market Spotlight 2021: Global Blood Therapeutics Leads Industry Sponsors -
The "Market Spotlight: Sickle Cell Anemia" report has been added to's offering.
Business Wire · 06/08 12:50
Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) Profit Outlook
With the business potentially at an important milestone, we thought we'd take a closer look at Global Blood...
Simply Wall St. · 06/08 07:42
The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck
Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week, headlining the biotech news flow of the week.
Benzinga · 06/07 12:52
Global Blood (GBT) Up 0.1% Since Last Earnings Report: Can It Continue?
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 06/04 15:31
Global Blood Therapeutics announces employment inducement grants
Global Blood Therapeutics (GBT) says that on June 1, 2021, the compensation committee of GBT's board granted 11 new employees options to purchase an aggregate of 35,500 shares of the company's
Seekingalpha · 06/04 12:23
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT’s board of directors granted 11 new employees options to purchase an ...
GlobeNewswire · 06/04 12:00
GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference on Tuesday,...
GlobeNewswire · 06/01 12:00
Baker Bros. Advisors Lp Buys Immunocore Holdings PLC, Instil Bio Inc, Talis Biomedical Corp, ...
GuruFocus News · 05/18 22:38
Yiheng Capital Llc Buys Global Blood Therapeutics Inc, JD. ...
GuruFocus News · 05/18 20:38
Bleichroeder LP Buys Cassava Sciences Inc, Duos Technologies Group Inc, Constellation ...
GuruFocus News · 05/17 13:38
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 05/14 11:59
BRIEF-Steven A. Cohen Reports 5.2% Passive Stake In Global Blood Therapeutics Inc As Of May 4, 2021 - SEC Filing · 05/13 21:34
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
SOUTH SAN FRANCISCO, May 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics,...
GlobeNewswire · 05/12 14:00
Elkhorn Partners Limited Partnership Buys International Flavors & Fragrances Inc, Amazon. ...
GuruFocus News · 05/11 20:38
Webull provides a variety of real-time GBT stock news. You can receive the latest news about Global Blood through multiple platforms. This information may help you make smarter investment decisions.
About GBT
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.